Kossel Medtech Included in Jiangsu's 2025 Science & Technology Enterprise IPO Cultivation Program

Oct 20, 2025 14:25 CST Updated 14:25

Kossel

Vascular Interventional Device Manufacturer and R&D Developer

Recently

Kossel Medtech, a company within Medpark, has been selected.

Provincial Science and Technology Enterprises of 2025

List of Enterprises Proposed for Inclusion in the IPO Cultivation Program

Jiangsu Province Science and Technology Enterprise IPO Cultivation ProgramThe focus is on high-tech enterprises, selecting a group of high-growth technology companies with sound governance structures, prominent core businesses, strong competitive abilities, and development potential for inclusion in the cultivation pool. The aim is to facilitate the listing and financing channels for high-tech enterprises and promote effective alignment between enterprises and the multi-level capital market.

Kossel Medtech (Suzhou) Co., Ltd

Kossel was established in November 2013 and is located in the Longshan Science Park, Phase 1 of the Jiangsu Medical Device Technology Park Medpark. It has now become a platform enterprise in the field of pan-vascular interventional devices, forming a "one core, three wings" business layout. Kossel is committed to building a "one-stop" treatment system for peripheral interventions. Its subsidiary, Haiyu Xincheng, focuses on the cardiac electrophysiology field, while its subsidiary, Mixin Medical, concentrates on the research and development of coronary intervention products and the transfer of overseas technologies. Another subsidiary, Haiwang Medical, is dedicated to overcoming the "bottleneck" technology of medical core raw materials.

Kossel Medtech is actively advancing the expansion and strategic layout of its markets both in China and internationally, with recent continuous good news—

▶Selected as a 2025 Jiangsu Gazelle Enterprise;

▶The self-developed peripheral thrombus aspiration system has successfully obtained the Class III medical device registration certificate from the National Medical Products Administration (NMPA);

▶Independently Developed Selethru^®NC PTCA Balloon Dilatation Catheter Gains Market Access in Brazil. The product has already been successively launched in multiple overseas markets, including the EU, the US, and Asia, earning widespread recognition for its excellent clinical performance.

▶Kossel's self-developed Selethru II (SC, NC26, Super NC) three types of PTCA balloon dilation catheters have obtained the Korean KFDA certificate.

Next step,Medpark will continue to optimize the industrial ecosystem, build a growth梯队 for innovative enterprises, actively connect with government departments, investment institutions and other多方 resources, and help enterprises in the park display more potential in the capital market through forms such as holding investment and financing meetings and listing counseling training.。